NEW YORK (GenomeWeb News) – Antigen Discovery said last week that it has received a $3 million Phase II Small Business Innovation Research grant to fund further development of its protein microarray-based serodiagnostic platform.
The Irvine, Calif.-based firm said that the platform is being developed for biodefense and emerging infectious disease applications. It will collaborate on the development program with researchers at the proteomics core facility of the Pacific Southwest Regional Center of Excellence at the University of California, Irvine.
“By using our novel protein array systems and statistical algorithms, we can rapidly discover antigen sets that will provide serological tests that discriminate between different infections, or even between different stages of the same infection,” Huw Davies, principal investigator on the grant, said in a statement.
The SBIR grant was awarded by the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources.